ArticlePloS one2025
Levonorgestrel-releasing intrauterine device treatment in heavy menstrual bleeding: Correlation with endometrial pathology and quality of life.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the study was to compare the effects of 52 mg Levonorgestrel-releasing intrauterine device (LNG-IUD), which is frequently used in patients with heavy menstrual bleeding, on quality of life according to benign endometrial pathology patterns. The study was designed retrospectively.143 patients between the ages of 28 and 54, who underwent endometrial sampling due to heavy menstrual bleeding and then the 52 mg LNG-IUD was placed, were included in the study. The most commonly observed results in endometrial pathology were divided into 2 groups: normal cycle patterns and hormonal imbalance patterns. Change in quality of life after LNG-IUD insertion was assessed using the Menorrhagia Multiattribute Scale (MMAS), the 36-Item Short Form Health Survey (SF-36), and the Beck Depression Inventory. In both groups, a significant increase was observed in all parameters of the SF-36 quality of life scale and the MMAS total score after LNG-IUD use compared to the pre-IUD period (p < 0.05) (MMAS increased from 51.9 ± 27.8% to 83.8 ± 26.2% at 6 months), and a significant decrease was observed in the Beck Depression Inventory score and depression rate (p < 0.05). However, there was no significant difference in the changes in quality of life questionnaires before and after LNG-IUD use between the groups (p > 0.05). The LNG-IUD provides substantial improvements in bleeding control and quality of life among women with heavy menstrual bleeding, and these effects are not influenced by endometrial pathology results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.